Please wait...
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Yes
100% of Medicare Part D and Medicare Advantage plans cover this drug.It depends. Which coverage stage are you in? Click on a tab below…
$1 – $17
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your pantoprazole sodium prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Pantoprazole is a proton pump inhibitor that decreases the amount of acid produced in the stomach.
Pantoprazole is used to treat erosive esophagitis (damage to the esophagus from stomach acid caused by gastroesophageal reflux disease, or GERD) in adults and children who are at least 5 years old. Pantoprazole is usually given for up to 8 weeks at a time while your esophagus heals.
Pantoprazole is also used to treat Zollinger-Ellison syndrome and other conditions involving excess stomach acid.
Pantoprazole is not for the immediate relief of heartburn symptoms.
Heartburn is often confused with the first symptoms of a heart attack. Seek emergency medical attention if you have chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, and a general ill feeling.
Long-term treatment with pantoprazole may also make it harder for your body to absorb vitamin B-12, resulting in a deficiency of this vitamin. Talk with your doctor if you need long-term pantoprazole treatment and you have concerns about vitamin B-12 deficiency.
Pantoprazole can cause kidney problems. Tell your doctor if you are urinating less than usual, or if you have blood in your urine.
Diarrhea may be a sign of a new infection. Call your doctor if you have diarrhea that is watery or has blood in it.
Pantoprazole may cause new or worsening symptoms of lupus. Tell your doctor if you have joint pain and a skin rash on your cheeks or arms that worsens in sunlight.
You may be more likely to have a broken bone while taking this medicine long term or more than once per day.
Heartburn can mimic early symptoms of a heart attack. Get emergency medical help if you have chest pain that spreads to your jaw or shoulder and you feel anxious or light-headed.
You should not use this medicine if:
you also take medicine that contains rilpivirine (Edurant, Complera, Juluca, Odefsey); or
you are allergic to pantoprazole or similar medicines (lansoprazole, omeprazole, Nexium, Prevacid, Prilosec, and others).
Tell your doctor if you have ever had:
low levels of magnesium in your blood;
lupus; or
osteoporosis or low bone mineral density.
You may be more likely to have a broken bone while using pantoprazole long-term or more than once per day. Talk with your doctor about ways to keep your bones healthy, especially if you are an adult over 50.
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
You should not breast-feed while using this medicine.
Pantoprazole is not approved for use by anyone younger than 5 years old.
Take pantoprazole exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.
Use the lowest dose for the shortest amount of time needed to treat your condition.
Pantoprazole is taken by mouth (oral) or given as an infusion into a vein (injection). A healthcare provider may teach you how to properly use the injection by yourself.
Pantoprazole tablets are taken by mouth, with or without food. The oral granules should be taken 30 minutes before a meal.
Do not crush, chew, or break the tablet. Swallow it whole.
The oral granules should be mixed with applesauce or apple juice and given either by mouth or through a nasogastric (NG) tube.
Read and carefully follow any Instructions for Use provided with your medicine. Ask your doctor or pharmacist if you have any questions.
Use this medicine for the full prescribed length of time, even if your symptoms quickly improve.
Call your doctor if your symptoms do not improve or if they get worse while you are using this medicine.
Pantoprazole can cause false results with certain medical tests. Tell the doctor or laboratory staff that you are using this medicine.
Pantoprazole may also affect a drug-screening urine test and you may have false results. Tell the laboratory staff that you use this medicine.
Store this medicine at room temperature away from moisture, heat, and light.
Usual Adult Dose for Erosive Esophagitis:
Treatment of Erosive Esophagitis:
40 mg orally once a day for up to 8 weeks; however an additional 8 weeks may be considered for patients who have not healed after the initial treatment. Safety and efficacy beyond 16 weeks of therapy have not been established.
Maintenance of Healing of Erosive Esophagitis:
40 mg orally once a day. Controlled studies have been limited to 12 months of pantoprazole therapy.
Usual Adult Dose for Gastroesophageal Reflux Disease:
Parenteral: 40 mg once a day for 7 to 10 days, administered via intravenous infusion over a period of 15 minutes. Intravenous therapy should be discontinued as soon as the patient is able to resume oral therapy.
Oral: 40 mg orally once a day, for short-term administration (up to 8 weeks); however an additional 8 weeks may be considered for patients who have not healed after the initial treatment. Safety and efficacy beyond 16 weeks of therapy have not been established.
Usual Adult Dose for Duodenal Ulcer:
Study (n=54)
40 mg orally once a day, dose was increased every 12 weeks by 40 mg increments to a maximum of 120 mg per day, for 28 weeks. Data have revealed that monotherapy with daily doses of 40 mg have been associated with complete duodenal ulcer healing in up to 87% and 94% of patients after 4 weeks and 8 weeks respectively.
Usual Adult Dose for Gastric Ulcer:
40 mg orally once a day. Data have revealed that monotherapy with daily doses of 40 mg have been associated with complete gastric ulcer healing in up to 87% and 97% of patients after 4 weeks and 8 weeks respectively.
Usual Adult Dose for Helicobacter pylori Infection:
Study (n=242) - Triple therapy:
40 mg orally twice daily for 7 days, commonly in conjunction with clarithromycin and either amoxicillin or metronidazole to eradicate Helicobacter pylori, followed with 40 mg pantoprazole orally once daily until day 28. Triple therapy has resulted in eradication rates of greater than 95%.
The QUADRATE Study (n=405) - Quadruple therapy:
40 mg orally twice daily for 7 days, concomitantly with bismuth subcitrate and tetracycline, both four times daily, and metronidazole 200 mg three times daily and 400 mg at bedtime. Helicobacter Pylori eradication was achieved in 82% of patients.
Usual Adult Dose for Zollinger-Ellison Syndrome:
Parenteral: 80 mg every 12 hours, administered by 15-minute infusion. Daily doses higher than 240 mg administered in equally divided doses by 15-minute infusion, or administered for more than 6 days have not been studied.
Oral: 40 mg twice daily, to a maximum of 240 mg per day. Some patients have received treatment with pantoprazole for more than 2 years.
Usual Adult Dose for Stress Ulcer Prophylaxis:
Study (n=21) - Stress Ulcer bleeding prophylaxis in the Critical Care Setting:
80 mg twice daily, as a bolus infusion over a period of 15 minutes, to a maximum daily dose of 240 mg, divided into three equal doses.
Study (n=20 ) - Peptic Ulcer rebleeding prophylaxis after hemostasis in the Critical Care Setting:
80 mg IV bolus, followed by continuous infusion of 8 mg/hr for 3 days, after which therapy may be continued with an oral PPI.
Usual Adult Dose for Peptic Ulcer:
Study (n=21) - Stress Ulcer bleeding prophylaxis in the Critical Care Setting:
80 mg twice daily, as a bolus infusion over a period of 15 minutes, to a maximum daily dose of 240 mg, divided into three equal doses.
Study (n=20 ) - Peptic Ulcer rebleeding prophylaxis after hemostasis in the Critical Care Setting:
80 mg IV bolus, followed by continuous infusion of 8 mg/hr for 3 days, after which therapy may be continued with an oral PPI.
Use the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not use two doses at one time.
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
This medicine can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.
Get emergency medical help if you have signs of an allergic reaction to pantoprazole: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
severe stomach pain, diarrhea that is watery or bloody;
sudden pain or trouble moving your hip, wrist, or back;
bruising or swelling where intravenous pantoprazole was injected;
kidney problems - urinating less than usual, blood in your urine, swelling, rapid weight gain;
low magnesium - dizziness, fast or irregular heart rate, tremors (shaking) or jerking muscle movements, feeling jittery, muscle cramps, muscle spasms in your hands and feet, cough or choking feeling; or
new or worsening symptoms of lupus - joint pain, and a skin rash on your cheeks or arms that worsens in sunlight.
Taking pantoprazole long-term may cause you to develop stomach growths called fundic gland polyps. Talk with your doctor about this risk.
If you use pantoprazole for longer than 3 years, you could develop a vitamin B-12 deficiency. Talk to your doctor about how to manage this condition if you develop it.
Common pantoprazole side effects may include:
headache, dizziness;
stomach pain, gas, nausea, vomiting, diarrhea;
joint pain; or
fever, rash, or cold symptoms (most common in children).
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all your other medicines. Some may interact with pantoprazole, especially:
digoxin;
methotrexate; or
a diuretic or "water pill."
This list is not complete. Other drugs may affect pantoprazole, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use pantoprazole only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Pantoprazole Sodium (www.drugs.com/pantoprazole.html).
More frequently reported side effects include: diarrhea and nausea. See below for a comprehensive list of adverse effects.
Applies to pantoprazole: oral packet, oral tablet enteric coated
Other dosage forms:
Along with its needed effects, pantoprazole may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pantoprazole:
Less common
Incidence not known
Some side effects of pantoprazole may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Incidence not known
Applies to pantoprazole: intravenous powder for injection, oral delayed release tablet, oral granule enteric coated
The most commonly reported side effects were headache, diarrhea, and injection site thrombophlebitis (in IV formulations).
Very common (10% or more): Headache (Up to 26.4%), taste pervasion (Up to 18.2%)
Common (1% to 10%): Dizziness, metallic/bitter taste, somnolence
Rare (0.01% to 0.1%): Taste disorders
Very rare (less than 0.01%): Change to the sense of taste, reduced movement, speech disorder
Frequency not reported: Paresthesia, vertigo
Postmarketing reports: Ageusia, dysgeusia
Headache was a very commonly reported side effect in pediatric patients 2 to 16 years of age. In adults, headache occurred most frequently in patients given quadruple therapy (pantoprazole, bismuth, metronidazole, tetracycline) for H pylori infections, but was also very common in triple therapy (pantoprazole, amoxicillin, clarithromycin).
Taste pervasion most frequently occurred in patients given triple therapy, but it was also very common in patients given quadruple therapy.
Very common (10% or more): Nasopharyngitis (up to 13.6%), pharyngolaryngeal pain (up to 13.2%)
Common (1% to 10%): Cough, nasal congestion, pharyngitis
Very rare (less than 0.01%): Change to the sense of smell, dyspnea
Frequency not reported: Upper respiratory tract infection
Nasopharyngitis and pharyngolaryngeal pain occurred in pediatric patients between the ages of 2 to 16 years.
Diarrhea occurred most frequently in patients given quadruple therapy (pantoprazole, bismuth, metronidazole, tetracycline) for Helicobacter pylori infections, but was also very common in triple therapy (pantoprazole, amoxicillin, clarithromycin).
Nausea, vomiting, abdominal pain, dry mouth, and constipation were more commonly reported in patients given triple therapy, compared to patients given quadruple therapy.
Fecal and/or tongue discoloration occurred more commonly in patients given quadruple therapy versus patients given triple therapy.
Very common (10% or more): Diarrhea (Up to 11.6%)
Common (1% to 10%): Abdominal pain, benign fundic gland polyps/fundic gland polyps, buccal inflammation, constipation, dry mouth, dyspepsia, fecal discoloration, flatulence, heartburn, nausea, oral moniliasis, pruritus ani, tongue discoloration, tongue pain, upper abdominal pain, vomiting
Uncommon (0.1% to 1%): Abdominal discomfort/distention, bloating, loose stools
Rare (0.01% to 0.1%): Colon polyp, rectal disorder
Very rare (less than 0.01%): Increased saliva
Frequency not reported: Clostridium difficile-associated diarrhea, severe eructation
Common (1% to 10%): Tiredness
Uncommon (0.1% to 1%): Asthenia, fatigue, malaise
Rare (0.01% to 0.1%): Body temperature increased, fever
Very rare (less than 0.01%): Pain, tinnitus
Frequency not reported: Facial edema
Confusion, depression, hallucinations, and disorientation, especially in predisposed patients, occurred with use, and was aggravated in patients with preexisting conditions.
Common (1% to 10%): Depression (and all aggravations)
Uncommon (0.1% to 1%): Sleep disorders
Rare (0.01% to 0.1%): Confusion (and all aggravations), disorientation (and all aggravations), hallucination (and all aggravations)
Very rare (less than 0.01%): Anxiety
Postmarketing reports: Insomnia
Severe hepatocellular damage leading to jaundice/hepatic failure is predicted to have a frequency of 1 in 1,000,000 patients.
Common (1% to 10%): Increased liver enzymes (transaminases, GGT)
Rare (0.01% to 0.1%): Increased bilirubin
Very rare (less than 0.01%): Cholestatic hepatitis, hepatitis, hepatocellular failure, jaundice
Frequency not reported: Hepatic effects, hepatocellular injury, liver function tests abnormal
Postmarketing reports: Hepatocellular damage
Common (1% to 10%): Exanthema/exanthemata, rash
Uncommon (0.1% to 1%): Eruption, increased sweating, pruritus
Rare (0.01% to 0.1%): Urticaria
Very rare (less than 0.01%): Erythema multiforme, flushing, Lyell syndrome, photosensitivity/photosensitivity reaction, severe skin reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)
Frequency not reported: Cutaneous lupus erythematosus, facial edema, fatal skin reactions, fatal TEN, subacute cutaneous lupus erythematosus
Common (1% to 10%): Chest pain
Rare (0.01% to 0.1%): Hypertension, peripheral edema, thrombophlebitis
Very rare (less than 0.01%): Circulatory collapse, flushing, hot flushes, substernal chest pain
Frequency not reported: Generalized edema
Muscle spasm occurred as a consequence of electrolyte disturbances.
Common (1% to 10%): Arthralgia
Uncommon (0.1% to 1%): Fracture of the hip/wrist/spine
Rare (0.01% to 0.1%): Myalgia
Very rare (less than 0.01%): Skeletal pain
Frequency not reported: Bone fracture, elevated creatine phosphokinase (CPK)/elevated creatine kinase (CK), muscle spasm, systemic lupus erythematosus
Postmarketing reports: Rhabdomyolysis
Hypocalcemia occurred in association with hypomagnesemia.
Anorexia commonly occurred in patients with H pylori.
Common (1% to 10%): Anorexia
Rare (0.01% to 0.1%): Hyperlipidemia, increased cholesterol, increased triglycerides, lipid increases, weight changes
Frequency not reported: Cyanocobalamin (vitamin B12) deficiency), electrolyte disturbances, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, potential for exacerbation of zinc deficiency
Common (1% to 10%): Injection site thrombophlebitis
Frequency not reported: Injection site reactions
Common (1% to 10%): Influenza-like symptoms, moniliasis
Rare (0.01% to 0.1%): Sepsis
Rare (0.01% to 0.1%): Anaphylactic reactions, anaphylactic shock, angioedema/Quincke's edema, hypersensitivity, hypersensitivity reactions
Frequency not reported: Allergic reactions
Postmarketing reports: Anaphylaxis
Rare (0.01% to 0.1%): Agranulocytosis, anemia
Very rare (less than 0.01%): Increased coagulation time, leukopenia, pancytopenia, thrombocytopenia
Uncommon (0.1% to 1%): Blurred vision, visual disturbances
Very rare (less than 0.01%): Conjunctivitis
Rare (0.01% to 0.1%): Gynecomastia
Very rare (less than 0.01%): Interstitial nephritis (with possible progression to renal failure)
Frequency not reported: Acute interstitial nephritis
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Pantoprazole Sodium (www.drugs.com/pantoprazole.html).
June 4, 2020
June 3, 2020
June 6, 2020
July 13, 2020
July 13, 2020
July 13, 2020
